Lucentis
E46708
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Lucentis canonical | 2 |
| ranibizumab | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T363286 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Lucentis Context triple: [Genentech, notableProduct, Lucentis]
-
A.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Lucentis Target entity description: Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
A.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
B.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
C.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
D.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
-
E.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anti-VEGF agent
ⓘ
biologic drug ⓘ ophthalmic drug ⓘ prescription medicine ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToRegulatoryCategory | prescription-only medicine ⓘ |
| contraindicatedIn |
known hypersensitivity to ranibizumab
ⓘ
ocular or periocular infection ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| hasAdministrationFrequency | monthly in many regimens ⓘ |
| hasAdministrationPattern | treat-and-extend regimens may be used ⓘ |
| hasApprovalYear | 2006 ⓘ |
| hasATCCode | S01LA04 ⓘ |
| hasCommonAdverseEffect |
conjunctival hemorrhage
ⓘ
eye pain ⓘ increased intraocular pressure ⓘ |
| hasDosageForm | solution for injection ⓘ |
| hasDrugClass |
monoclonal antibody fragment
ⓘ
vascular endothelial growth factor inhibitor ⓘ |
| hasGenericName |
ranibizumab
ⓘ
linked to:
Lucentis
|
| hasIndicationType |
treatment of choroidal neovascularization
ⓘ
vision preservation ⓘ |
| hasMolecularType | humanized monoclonal antibody fragment ⓘ |
| hasRouteOfAdministration | intravitreal injection ⓘ |
| hasSeriousAdverseEffect |
endophthalmitis
ⓘ
retinal detachment ⓘ |
| hasTherapeuticArea | ophthalmology ⓘ |
| hasTherapeuticGoal |
improve visual acuity
ⓘ
slow progression of vision loss ⓘ |
| isAdministeredBy | ophthalmologist ⓘ |
| isRelatedDrug |
aflibercept
ⓘ
bevacizumab ⓘ
linked to:
Avastin
faricimab ⓘ |
| isUsedFor |
diabetic macular edema
ⓘ
diabetic retinopathy ⓘ macular edema following retinal vein occlusion ⓘ myopic choroidal neovascularization ⓘ neovascular age-related macular degeneration ⓘ wet age-related macular degeneration ⓘ |
| marketedBy |
Genentech
ⓘ
Novartis ⓘ |
| mechanismOfAction |
inhibits VEGF-A
ⓘ
reduces abnormal blood vessel growth in the retina ⓘ reduces vascular permeability in the retina ⓘ |
| targets | vascular endothelial growth factor A ⓘ |
| treatsAnatomicalSite |
macula
ⓘ
retina ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Lucentis Description of subject: Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.